A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma

(2021) Giulia Agliardi et al.   Nature Communications

OSskcm: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles

(2020) Lu Zhang et al.   Cancer Cell International

Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer

(2020) Wentao Kuai et al.   Biomed Research International

Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours

(2020) Aslan Mansurov et al.   Nature Biomedical Engineering

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

(2019) Zhida Liu et al.   Science Immunology

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

(2019) Karen A. Autio et al.   CLINICAL CANCER RESEARCH

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

(2019) Zhichen Sun et al.   Nature Communications

OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts

(2019) Zhongyi Yan et al.   Frontiers in Oncology

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

(2018) Jianfang Liu et al.   CELL

M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma

(2018) Magdalena Jarosz-Biej et al.   PLoS One

PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer

(2018) Michitaka Nakano et al.   CANCER SCIENCE

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

(2018) Chien-Chun Steven Pai et al.   JOURNAL OF CLINICAL INVESTIGATION

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma

(2016) Clémence Granier et al.   CANCER RESEARCH

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

(2015) Alice Tzeng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The immunocytokine NHS-IL12 as a potential cancer therapeutic

(2015) Jonathan Fallon et al.   Oncotarget

Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients

(2014) H. R. Ali et al.   ANNALS OF ONCOLOGY

New insights into IL-12-mediated tumor suppression

(2014) S Tugues et al.   CELL DEATH AND DIFFERENTIATION

Immunoexpression of Metalloproteinases 2 and 14 and TIMP-2 Inhibitor in Main Types of Primary Gastric Carcinomas and Lymph Node Metastasis

(2014) Daniel Cordeiro Gurgel et al.   PATHOLOGY & ONCOLOGY RESEARCH

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

(2013) L. R. Desnoyers et al.   Science Translational Medicine

The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel

(2012) N. Pasche et al.   CLINICAL CANCER RESEARCH

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

(2012) Oran Erster et al.   JOURNAL OF CONTROLLED RELEASE

Ex Vivo Interleukin-12-Priming During CD8+ T Cell Activation Dramatically Improves Adoptive T Cell Transfer Antitumor Efficacy in a Lymphodepleted Host

(2012) Mark P. Rubinstein et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model

(2012) Bang-Wen Xie et al.   PLoS One

Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases

(2011) John Puskas et al.   IMMUNOLOGY

The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis

(2011) Catherine E. Steding et al.   IMMUNOLOGY

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

(2010) Kai Kessenbrock et al.   CELL

Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer

(2010) María Fernanda García et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

(2009) Michelle R. Simpson-Abelson et al.   CLINICAL IMMUNOLOGY

Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database

(2008) P. M. McGowan et al.   ANNALS OF ONCOLOGY